Bristol Myers Squibb Terminates Agreements With Immatics Due To Ongoing Portfolio Prioritization Efforts Within BMS For Allogeneic Programs; Collaboration With BMS Under The 2019 Multi-Target TCR-T Strategic Collaboration Agreement Remains Ongoing
Bristol Myers Squibb Terminates Agreements With Immatics Due To Ongoing Portfolio Prioritization Efforts Within BMS For Allogeneic Programs; Collaboration With BMS Under The 2019 Multi-Target TCR-T Strategic Collaboration Agreement Remains Ongoing
On December 12, 2024, Bristol Myers Squibb ("BMS") notified Immatics N.V. (the "Company") that, due to ongoing portfolio prioritization efforts within BMS, it has elected to terminate the collaboration agreement, dated June 1, 2022, between Celgene Switzerland LLC and Immatics US, Inc., relating to the development of allogeneic programs, and the opt-in agreement, dated April 28, 2023, between Celgene Switzerland LLC and Immatics GmbH, relating to a target under the parties' multi-target TCR-T strategic collaboration. The terminations are effective as of March 12, 2025. The Company is not obligated to refund BMS any part of the $60 million upfront payment received under the collaboration agreement or the $15 million opt-in payment received under the opt-in agreement. The Company's collaboration with BMS under the 2019 multi-target TCR-T strategic collaboration agreement remains ongoing.
2024年12月12日，百時美施貴寶（"BMS系統"）通知Immatics N.V.（"公司"），由於BMS系統正在進行的投資組合優先化工作，決定終止2022年6月1日Celgene Switzerland LLC與Immatics US, Inc.之間關於同種異體項目開發的合作協議，以及2023年4月28日Celgene Switzerland LLC與Immatics GmbH之間關於雙方多靶點TCR-t戰略合作的選擇協議。終止自2025年3月12日起生效。公司不需要退還BMS系統在合作協議下收到的6000萬美元預付款或在選擇協議下收到的1500萬美元選擇付款。公司與BMS系統在2019年多靶點TCR-t戰略合作協議下的合作仍在繼續。
譯文內容由第三人軟體翻譯。
